Vancouver, British Columbia (Newsfile Corp. - June 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized
EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous Defence Therapeutics Inc.: DEFENCE BEGINS TESTING ITS ARM VACCINE AGAINST PANCREATIC CANCER 06.06.2023 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement.
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had tumor biomarker reduction (77%) with 32% having complete clearanceRobust
Study findings demonstrated that states that expanded Medicaid had improved survival rates in patients with pancreatic and gastric cancers, with greater improvements in Black patients for some analyses.